Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,035 matching trials from the live ClinicalTrials.gov search.
Conditions
Sarcoma
Interventions
NY-ESO-1 peptide vaccine, sargramostim
Biological
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Conditions
Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma, Chondrosarcoma
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 6 more
Conditions
Ovarian Cancer
Interventions
filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Results available

Stem Cell Injection in Cancer Survivors

NCT02509156
Conditions
Cardiomyopathy Due to Anthracyclines
Interventions
Allo-MSCs, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Conditions
Uterine Fibroid
Interventions
Perfluten
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Sarcoma
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
10 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions
Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab
Procedure · Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Sarcoma, Childhood Sarcoma of Soft Tissue
Interventions
Non Intervention Study
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
12 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Berkeley, California • Beverly Hills, California • Encino, California + 17 more
Conditions
Postoperative Pain, Fibroid Uterus
Interventions
Bupivacain, Saline
Drug
Lead sponsor
Joseph Findley MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Beachwood, Ohio
Conditions
Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma, DIPG Brain Tumor
Interventions
Eflornithine (DFMO), AMXT 1501 Dicaprate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 26 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more
Conditions
Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7
Interventions
Alisertib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
235
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 153 more
Recruiting No phase listed Observational Accepts healthy volunteers

Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients

NCT06875700
Conditions
Leiomyosarcoma
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Bone Sarcomas, Financial Toxicity
Interventions
data collection
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Severe Chronic Active EBV Infection Syndrome (SCAEBV), Leiomyosarcoma
Interventions
LMP1/2 CTLs (Group A), LMP1/2 CTLs (Group B)
Drug
Lead sponsor
Catherine Bollard
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Spinal Tumor
Interventions
Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation, Questionnaires
Radiation · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancers, Brain Metastases
Interventions
Gamma Knife Radiosurgery
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lymphedema
Interventions
Medical Examination, Questionnaire Administration, Shear Wave Elastography
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
22 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Neutropenia, Sarcoma
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 35 more
Conditions
Leiomyosarcoma
Interventions
Blood and Tissue collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
Conditions
Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Olaparib, Temozolomide, Irinotecan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • Memphis, Tennessee
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor, Premenopausal
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration, Ultrasonography
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more